Maki Nagata
Papers
2
Total Citations
10
H-Index
2
About
Dr. Maki Nagata is a leading urologic oncologist whose research bridges precision oncology and surgical innovation. Her work centers on two critical frontiers: the genomic characterization of rare, aggressive bladder cancers and the refinement of risk stratification for prostate cancer surgery. In a landmark 2022 case study, Dr. Nagata demonstrated that a patient with plasmacytoid variant bladder cancer—a notoriously lethal subtype accounting for only 1% of cases—achieved a pathological complete response to pembrolizumab after genomic analysis, offering a new therapeutic lifeline for this aggressive disease. This work has already garnered significant attention (6 citations) for its translational impact. On the surgical side, Dr. Nagata developed and validated a novel nomogram (2023, 4 citations) to identify candidates for extended pelvic lymph node dissection in Japanese prostate cancer patients undergoing robot-assisted radical prostatectomy. By integrating clinical variables specific to the robotic era, her tool improves the precision of lymph node invasion risk assessment, potentially sparing low-risk patients from unnecessary surgery while ensuring high-risk patients receive optimal treatment. Dr. Nagata’s dual focus on rare tumor biology and surgical decision-making exemplifies how molecular insights and clinical tools can converge to improve outcomes in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2